Global Automated Microbiology Market 2021 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Automated Microbiology Market 2021 (Includes Business Impact of COVID-19)
Global Automated Microbiology Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2030 is a recent report generated by Trusted Business Insights. The global automated microbiology market report has been segmented on the basis of deployment, offering, vertical, and region.
Request Covid - 19 Impact
The global Automated Microbiology market size was valued at USD$ 4.82 billion in 2020 and is projected to reach UDS$11.61 billion by 2030, and is anticipated to expand at a CAGR of 9.19% over the forecast period from 2020 to 2030.


Global Automated Microbiology Market: Overview


Automated microbiology is one of the key requirements for fast and more accurate results in field of clinical laboratories. Automated microbiology is used to identify the virus or bacteria. Automated microbiology is used in the clinical chemistry and clinical hematology areas of diagnostics laboratories.


Global Automated Microbiology Market: Dynamics


Increasing frequency of pathogen causes chronic disease. To prevent form diseases many laboratories are using automated microbiology that can detect the bacteria in the early stage, making it easier for professionals to detect the virus or bacteria. Automated microbiology helps in detecting bacteria such as parasites, fungus, viroid, etc. These bacteria can cause unpleasant disease for example, rubella, chickenpox, mumps. The lack of professionals in lab testing and increasing demand for laboratory testing have lead the growth of the global automated microbiology in the market.

Increasing need for fast results with high accuracy, and rising concerns about health safety and increasing number of footfalls in hospitals is expected to result in requirement for laboratory services. These factors are expected to support growth of the target market.

However, high cost of manufacturing of equipment might hinder revenue growth of the global market.  In addition, dearth of highly skilled professionals to operate the equipment may hamper the growth of the market.

Key trend observed in the market is that the major companies are focusing on developing new systems with enhanced technology such as high thermal stability and powerful proprietary algorithms, in order to increase sales and sustain in the market.


Global Automated Microbiology Market: Segmental Analysis


Among the deployment segment, the monoclonal antibodies segment is expected to dominate in the global market with highest revenue contribution. The clinical laboratories segment is estimated to account for second-highest revenue share in the target market.

Global Automated Microbiology Market: Regional analysis

North America market is estimated to account for major share in terms of revenue in the global market, owing to increasing investments in R&D and development of new technologies and introduction of high-tech laboratory tests. Moreover, increasing prevalence of chronic diseases and disorders is expected to result in rising need for laboratory tests. The Asia Pacific market is projected to register significant CAGR owing to growing medical tourism industry in countries in the region.


Below are the active patents related to Automated Microbiology Market.


Patent Number: US20110124028A1

Automated microbial detection apparatus

Abstract

A method and automated apparatus for rapid non-invasive detection of a microbial agent in a test sample is described herein. The apparatus may include one or more means for automated loading, automated transfer and/or automated unloading of a specimen container. The apparatus also includes a detection system for receiving a detection container, e.g., container or vial, containing a biological sample and culture media. The detection system may also include one or more heated sources, holding structures or racks, and/or a detection unit for monitoring and/or interrogating the specimen container to detect whether the container is positive for the presence of a microbial agent therein. In other embodiment, the automated instrument may include one or more, bar code readers, scanners, cameras, and/or weighing stations to aid in scanning, reading, imaging and weighing of specimen containers within the system.

Application File Date: 2010-05-14

Application Granted Date: 2018-06-26

Current Assignee: Biomerieux Inc

Patent Number: US7238519B2

Automated immunoassay cassette, apparatus and method

Abstract

An immunoassay cassette, apparatus, and method for detecting an analyte in a liquid body-fluid sample are disclosed. The cassette has a body and a support mounted on the body, for movement relative to the body to first and second transfer positions. Sample supplied to a sample well in the cassette body is transferred to a reagent reservoir on the cassette body, by moving the support to its first transfer position. Here the sample reacts with a first reagent composition in the reservoir effective to form a modified sample. The modified sample is then transferred to a reagent strip on the support by moving the support to its second transfer position. The reagent strip has a transfer zone at which sample material is transferred to the strip, a second reagent composition effective to react with the modified sample to form a detectable analyte-dependent product, and a detection zone located downstream at which the detectable product can be observed. By controlling movement of the support to its first and second positions, the cassette can effectively handle a variety of samples having different flow rates.

Application File Date: 2004-12-17

Application Granted Date: 2007-07-03

Current Assignee: Alere San Diego Inc

Patent Number: US7220595B2

Automated immunoassay cassette, apparatus and method

Abstract

An immunoassay cassette, apparatus, and method for detecting an analyte in a liquid body-fluid sample are disclosed. The cassette has a body and a support mounted on the body, for movement toward and away from a sample transfer position. Sample supplied to a sample well in the cassette body is taken up by a reagent reservoir containing a first reagent composition effective to form a modified sample. The support provides a reagent strip having a transfer zone that is brought into contact with the reservoir, when the support is in the transfer position, a detection zone located downstream of the transfer zone, and a second reagent composition effective to react with the modified sample to form a detectable analyte-dependent product. By controlling movement of the support, volume and rate of sample flow from the reservoir to the strip can be controlled to optimize and/or standardize sample-transfer conditions in the assay.

Application File Date: 2003-06-06

Application Granted Date: 2007-05-22

Current Assignee: Alere San Diego Inc

Global Automated Microbiology Market Segmentation:

Segmentation by deployment:

  
DNA & RNA probe technology
  
Detection techniques
  
Immunoassays
  
Monoclonal antibodies

Segmentation by end user:

  
Clinical Laboratories
  
Biotechnology Industries
  
Others


Key Market Players included in the report:


  
Abbott Laboratories.
  
Affymetrix, Inc.
  
Agilent Technologies, Inc.
  
Alere Inc.
  
BD (Becton Dickinson)
  
Beckman Coulter
  
Becton Dickinson and Company
  
BioMerieux S.A.
  
Bio-Rad Laboratories Inc.
  
Bruker Corporation
  
Cepheid Inc.
  
Danaher Corporation
  
Gene-ProbeInc.
  
Hologic Inc.
  
QIAGEN GmbH
  
Roche Diagnostics


Below are the key development related to Automated Microbiology Market in 2020 and 2021.


May  2021: BD Leverages Artificial Intelligence To Transform Microbiology Urine Testing. U.S. Launch of BD Kiestra™ Urine Culture Application Helps Accelerate Workflow and Drive Lab Efficiency. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the U.S. launch of a Urine Culture Application for use with the BD Kiestra™ lab automation incubation and imaging system that can transform the way microbiology labs approach urine culture analysis. Designed using artificial intelligence (AI) and leveraging the quality of BD BBL™ plated media, the application uses digital imaging and software algorithms to determine the amount of growth on a urine culture plate from clean caught and catheterized samples. The BD Kiestra™ systems intelligent incubation and imaging device uses high-throughput robotics to perform time series imaging, coupled with machine learning so that plates with no significant growth can be released for disposal and plates with significant growth automatically go into a queue for clinician analysis. In many labs, urine cultures make up a significant part of the daily workload — however, the majority of those samples have no growth or non-significant growth and dont require any additional work-up. Batch review of large volumes of plates with non-significant growth and release can help medical laboratorians focus their time and expertise on more clinically relevant tasks. Source

May 2021: PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC. PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Immunodiagnostic Systems Holdings PLC (LSE: IHS) (“IDS”) are pleased to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire IDS for approximately $155 million (£110 Million). The transaction has a total enterprise value of approximately $124 million (£88 Million) and is expected to close early in the third quarter of 2021, subject to approvals from the shareholders of IDS, sanction by the High Court of Justice in England and Wales and other customary closing conditions for a public takeover in the United Kingdom.Through this acquisition, PerkinElmer will be able to grow its overall Diagnostics business and specifically its immunodiagnostics segment. Moreover, the deal will enable PerkinElmer to combine its channel expertise and testing capabilities with IDS’s best-in-class chemiluminescence products in endocrinology, autoimmunity and infectious diseases to better serve customers around the world.Source

April 2021: Luminex Acquisition by DiaSorin. We are pleased to announce that we signed an agreement for DiaSorin S.p.A. (FTSE MIB: DIA) to acquire Luminex Corporation (NASDAQ: LMNX).
We believe that this transaction creates significant opportunities for both Luminex and DiaSorin customers to gain access to broader assay portfolios, enhanced research tools, and expanded support services and that the combination will strengthen the combined companies’ existing offerings and drive new partnerships in the biopharmaceutical, academic, and clinical spaces. Source